Sangamo Therapeutics (NASDAQ:SGMO) Trading 25.5% Higher – Still a Buy?

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were up 25.5% during trading on Monday . The company traded as high as $2.59 and last traded at $2.57. Approximately 4,776,585 shares were traded during mid-day trading, a decline of 29% from the average daily volume of 6,772,263 shares. The stock had previously closed at $2.05.

Analysts Set New Price Targets

A number of analysts have recently weighed in on SGMO shares. Barclays increased their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. StockNews.com raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, December 10th. Finally, Truist Financial raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Sangamo Therapeutics Stock Up 6.6 %

The firm has a market capitalization of $588.38 million, a price-to-earnings ratio of -3.76 and a beta of 1.15. The firm’s 50 day moving average is $1.88 and its 200 day moving average is $1.10.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. During the same period last year, the company posted ($0.34) EPS. On average, sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently modified their holdings of the business. Meritage Portfolio Management boosted its holdings in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 57,125 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the last quarter. Finally, Golden State Equity Partners grew its position in Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 69,368 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.